DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Current Treatment: Physician Insights – Squamous Cell Carcinoma of the Head and Neck (US)
The treatment of non-nasopharyngeal SCCHN is heterogeneous and guided by multiple factors, such as tumor burden and growth, the line of therapy, and prior treatment exposure. In the locoregionally…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Treatment Sequencing – Squamous Cell Carcinoma of the Head and Neck (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Breast Cancer – Current Treatment – Current Treatment: Physician Insights – Breast Cancer (US)
The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) combined with endocrine therapy, are established…
Hepatocellular Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche’…
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)
Immune checkpoint inhibitors continue to anchor the treatment of non-small-cell lung cancer (NSCLC), while rapid advances in biomarker-driven strategies are accelerating patient segmentation and…
Non-Small-Cell Lung Cancer – Current Treatment – Treatment Sequencing – Non-Small-Cell Lung Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
